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Relationship Between Age at Menopause,
Obesity, and Incident Heart Failure: The
Atherosclerosis Risk in Communities Study
Imo A. Ebong , MD, MS; Machelle D. Wilson , PhD; Duke Appiah, PhD; Erin D. Michos , MD, MS;
Susan B. Racette , PhD; Amparo Villablanca, MD; Khadijah Breathett , MD, MS; Pamela L. Lutsey , PhD, MpH;
Melissa Wellons, MD; Karol E. Watson , MD, PhD; Patricia Chang, MD, MHS; Alain G. Bertoni, MD, MPH
BACKGROUND: The mechanisms linking menopausal age and heart failure (HF) incidence are controversial. We investigated for
heterogeneity by obesity on the relationship between menopausal age and HF incidence.
METHODS AND RESULTS: Using postmenopausal women who attended the Atherosclerosis Risk in Communities Study Visit 4,
we estimated hazard ratios of incident HF associated with menopausal age using Cox proportional hazards models, testing
for effect modification by obesity and adjusting for HF risk factors. Women were categorized by menopausal age: <45 years,
45 to 49 years, 50 to 54 years, and ≥55 years. Among 4441 postmenopausal women, aged 63.5±5.5 years, there were 903
incident HF events over a mean follow-up of 16.5 years. The attributable risk of generalized and central obesity for HF incidence was greatest among women who experienced menopause at age ≥55 years: 11.09/1000 person-years and 7.38/1000
person-years, respectively. There were significant interactions of menopausal age with body mass index and waist circumference for HF incidence, Pinteraction 0.02 and 0.001, respectively. The hazard ratios of incident HF for a SD increase in body mass
index was elevated in women with menopausal age <45 years [1.39 (1.05–1.84)]; 45–49 years [1.33, (1.06–1.67)]; and ≥55 years
[2.02, (1.41–2.89)]. The hazard ratio of incident HF for a SD increase in waist circumference was elevated only in women with
menopausal age ≥55 years [2.93, (1.85–4.65)].
CONCLUSIONS: As obesity worsened, the risk of developing HF became significantly greater when compared with women
with lower body mass index and waist circumference, particularly among those who had experienced menopause at age
≥55 years.
Key Words: heart failure ■ menopause ■ obesity

M

enopause has emerged as a female-
specific
risk factor for cardiovascular diseases1 such
as heart failure (HF). Although early menopause (the occurrence of menopause at <45 years of
age) has been associated with HF in prior studies,2–4
there is a gap in knowledge regarding the influence
of late menopause, the occurrence of menopause at
≥55 years, on HF incidence. The influence of obesity
on the association between menopausal age and HF
incidence has not been previously investigated. HF

affects ≈3.2 million American women.5 Approximately
10% of women experience natural menopause before
45 years of age.3 It is important to understand the
associations between menopausal age and HF incidence to better target high-risk women for risk factor
modification and close surveillance.
Menopause is also associated with obesity.6
Underweight women have an increased risk of experiencing early menopause, while overweight and obese
women are more likely to experience menopause at
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CLINICAL PERSPECTIVE
What Is New?

• As obesity worsens in women, the risk of developing heart failure significantly increases when
compared with women with lower body mass
index and waist circumference, particularly in
those with menopausal age ≥55 years.

What Are the Clinical Implications?

• Maintenance of a healthy body weight and waist
circumference may be protective against developing HF, particularly among women who experience menopause at ≥55 years.
• A public heath campaign advocating weight
management may be useful for heart failure prevention in postmenopausal women.

Nonstandard Abbreviations and Acronyms
ARIC
ELITE
SWAN
WC

Atherosclerosis Risk in Communities
Study
Early versus Late Intervention Trial with
Estradiol
Study of Women’s Health across the
Nation
waist circumference

later ages.6 This association is complicated because
body fat deposition increases during the menopausal
transition and postmenopausal period.7–9 Adipose
tissue is a major source of estrogenic and androgenic steroids,10 and the changes in sex hormone
concentrations that occur after the menopausal transition could also influence the regulation of body fat
deposition.11
Generalized and central obesity have been associated with HF incidence in multiple studies12–16 and account for 14% of HF cases in women.5 The relationship
between obesity and incident HF is related to hemodynamic and anatomic cardiac changes, hormonal and
metabolic changes, inflammation, and comorbidities
resulting from excess body fat.17–19 In this study, we
investigated for the presence of heterogeneity by obesity on the relationship between menopausal age and
HF incidence in postmenopausal women of the ARIC
study (Atherosclerosis Risk in Communities) at Visit 4.
We hypothesized that (1) generalized obesity, indicated
by body mass index (BMI), and (2) central obesity, indicated by waist circumference (WC), will moderate
the association between menopausal age and HF incidence with greater HF risks in obese women who

experienced menopause before 45 years of age. Our
conceptual model is depicted in Figure 1.

METHODS
Study Population and Sample
Instructions on how to obtain the data set used for this
study can be obtained directly from the ARIC study
at https://sites.cscc.unc.edu/aric. The ARIC study
prospectively enrolled 15 792 participants including 8710 women, from 4 US communities: Forsyth
County, North Carolina; Jackson, Mississippi; suburbs
of Minneapolis, Minnesota; and Washington County,
Maryland between 1987 and 1989. Six follow-up Visits
have been completed; Visit 2 (1990–
1992), Visit 3
(1993–1995), Visit 4 (1996–1998), Visit 5 (2011–2013),
Visit 6 (2016–2017), and Visit 7 (2018–2019). The ARIC
study design and methods have been published.20
ARIC participants were contacted annually before
2012 and semi-annually afterwards through telephone
calls. The ARIC study protocol was approved by
Institutional Review Boards at participating institutions
and informed consent was obtained from participants.
ARIC Visit 4 serves as baseline for our analysis.
Women were considered initially ineligible if they reported having menstrual periods in the preceding
2 years before the Visit 4 examination. We included
women with natural or surgical menopause at ARIC
Visit 4 (n=5539). In keeping with prior ARIC study analyses, we sequentially excluded Black women from the
Minnesota or Maryland centers (n=15) because of their
small numbers. We also excluded women who were
not of Black or White race (n=26). Next, we excluded
women who were missing information on menopausal
age (n=626), those who had undergone hysterectomy without bilateral oophorectomy before 55 years
of age (n=23) because of inability to accurately define
their menopause age, those with missing information
on BMI or WC (n=10), women who were underweight,
BMI <18.5 kg/m2 (n=53), those missing information on
HF incidence (n=279), and those with prevalent HF at
Visit 4 (n=66). Our final sample size of 4441 postmenopausal women included 3636 women with natural
menopause and 808 with surgical menopause. Our
sample size flow diagram is shown in Figure S1.

Baseline Measurements at Visit 4
Standardized protocols were used to collect data on
participant characteristics and known HF risk factors21,22
such as diabetes, hypertension, kidney function, inflammation, left ventricular hypertrophy, and myocardial
infarction (MI) at all follow-up visits. Chronological age,
menopausal status, menopausal age, annual income
(an indicator of socioeconomic status), smoking, alcohol
use, and medication use were obtained using self-report.
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Figure 1. Conceptual model depicting the influence of obesity on the relationship between
menopausal age and heart failure.

BMI was calculated by dividing weight by the square
of height. Women were classified as normal weight if
BMI was between 18.5 and 24.9 kg/m2, overweight if
BMI was between 25.0 and 29.9 kg/m2, and obese if
BMI was ≥30.0 kg/m2. WC was measured at the umbilicus in light clothing. Women were classified as having
central obesity if waist circumference was >88 cm. Two
measurements of resting blood pressure were obtained
and the average value was used. Diabetes was defined
as fasting blood glucose ≥126 mg/dL, nonfasting blood
glucose ≥200 mg/dL, or self-reported physician diagnosis of/or treatment for diabetes. Glucose was measured
using the hexokinase method.23 Fasting plasma total
cholesterol and high-density lipoprotein cholesterol were
measured by enzymatic methods.24 Glomerular filtration
rate was estimated using the chronic kidney disease
epidemiology collaboration equation.3 High-sensitivity
C-
reactive protein was measured with an immunonephelometric assay on a BNII autoanalyzer (Siemens
Healthcare Diagnostics, Deerfield, Illinois) with a coefficient of reliability of 0.99.25 Left ventricular hypertrophy
was defined by Cornell criteria using an ECG. Prevalent
coronary heart disease was based on information from
annual telephone calls, review of hospital discharge diagnoses, and death certificates, and defined as definite
or probable MI, definite fatal coronary heart disease,
or cardiac procedure on or before Visit 4.26 After the
baseline visit, all MI events in the ARIC study have been
adjudicated.27 Prevalent MI at Visit 4 is a combination
of self-report (and MI detected on ECG) at Visit 1 and
adjudicated events before Visit 4. Prevalent HF at Visit
4 was determined from hospital discharge lists or death
certificates as International Classification of Diseases
(ICD), Ninth Revision code 428 or ICD, Tenth Revision
code I50.26

Incident HF Definition
Incident HF was defined as the first hospitalization or
death from HF. Hospital records of ARIC participants
were reviewed to obtain information on HF hospitalizations, and death certificates were examined to identify
HF-related deaths.28 ARIC participants were contacted
annually before 2012 and semi-
annually afterwards
to obtain information on HF events. Before 2005, HF
events were determined from hospital discharge lists
or death certificates that included ICD Ninth Revision
code 428 or ICD Tenth Revision code I50 as a primary
or secondary diagnosis or among the listed causes of
death.26 HF events after January 1, 2005 have been
adjudicated by an expert panel.29 This study utilized HF
information based on ICD codes and those available
until December 31, 2017.

Statistical Analysis
In keeping with prior studies,3,4 participants were categorized according to menopausal age: <45, 45–49,
50–54, and ≥55 years. Highly skewed variables were
log-transformed. Data are presented according to categories of menopausal age using means (SD) or median (interquartile range) for continuous variables and
percentage for categorical variables, and comparisons
were made between the groups using χ2 tests for categorical variables and analysis of variance for continuous variables. Kaplan–Meier plots for incident HF are
displayed according to menopausal age categories
using chronological age at time of event or censoring
on the time scale, and compared using the log-rank
test. We calculated incidence rates of HF according to
obesity and menopausal age categories. Participants
were censored if they were lost to follow-up or failed

J Am Heart Assoc. 2022;11:e024461. DOI: 10.1161/JAHA.121.0244613

Ebong et al

Menopause, Obesity, and Heart Failure

Table 1. Characteristics of Study Participants at ARIC Visit 4 According to Menopausal Age Categories; The ARIC Study,
1996 to 1998
Menopausal age category, y
Characteristics

<45

46– 49

50– 54

≥55

Number of participants

1200

1515

1468

258

P value

Chronological age, y

63.5 (5.7)

63.0 (5.4)

63.6 (5.4)

65.7 (4.8)

<0.0001

Menopausal age, y

39.5 (3.3)

46.9 (1.5)

51.3 (1.4)

55.7 (1.1)

<0.0001

White race, %

65.7

76.8

83.7

79.1

<0.0001

Forsyth county, NC, %

25.1

23.8

23.2

24.8

Jackson, MS, %

30.9

21.7

14.8

18.2

Visit 4 center

<0.0001

Minneapolis, MN, %

18.8

26.3

33.3

26.0

26.0

25.3

28.2

28.8

31.0

Current cigarette smoking, %

15.5

14.4

11.1

6.6

<0.0001

Current alcohol use, %

34.6

45.6

47.6

41.9

<0.0001

32.8

39.8

46.1

50.0

Hormone therapy use
Never, %

<0.0001

Past, %

62.8

56.4

49.1

45.0

Current, %

4.5

3.8

4.8

5.0

47.1

38.5

36.9

39.6

Annual income
<$25 000, %

<0.0001

≥$25 000 to <$50 000, %

32.0

35.6

35.8

35.3

≥$50 000 to <$100 000, %

17.3

20.8

21.5

20.4

≥$100 000, %

4.7

3.7

5.1

5.7

Body mass index, kg/m2

28.9 (5.7)

28.7 (6.1)

28.8 (6.1)

28.8 (5.7)

0.91

Waist circumference, cm

101.4 (15.5)

100.7 (15.9)

100.5 (15.7)

100.8 (15.0)

0.58

Diabetes, %

17.8

15.2

12.8

15.6

0.006

Hypertension, %

55.4

47.5

45.2

47.3

<0.0001

Total cholesterol, mg/dL

207.8 (36.6)

209.3 (36.4)

208.3 (35.8)

210.6 (37.3)

0.56

High-density lipoprotein
cholesterol, mg/dL

55.7 (16.3)

55.8 (17.3)

54.7 (15.7)

54.0 (15.2)

0.14

Statin therapy, %

10.5

9.8

10.5

9.0

0.79

Glomerular filtration rate, mL/min
per 1.73 m2

86.6 (17.3)

86.4 (16.4)

86.2 (15.1)

82.7 (15.9)

0.005

High-sensitivity C-reactive
protein, mg/L

3.5 (1.5, 7.0)

3.2 (1.3, 6.6)

2.7 (1.2, 5.5)

2.8 (1.0, 6.1)

<0.0001

Left ventricular hypertrophy, %

4.8

3.3

4.3

5.1

0.36

Coronary heart disease, %

4.0

3.4

3.3

3.5

0.83

Values are means (SD) or median (interquartile range) unless otherwise stated. High-sensitivity C-reactive protein was log transformed because of skewness.
P values were determined using χ2 tests for categorical variables and Analysis of Variance for continuous variables. Missing values were <3% for all variables.
ARIC indicates Atherosclerosis Risk in Communities Study; MN, Minnesota; MS, Mississippi; and NC, North Carolina.

to experience HF before administrative censoring on
December 31, 2017.
Cox proportional hazards models were used to
examine the associations between menopausal age
categories and HF incidence, testing for effect modification by obesity and sequentially adjusting for patient characteristics and known HF risk factors. There
was a significant interaction between menopausal age
category and BMI for HF incidence (Pinteraction 0.02).
We calculated unadjusted and adjusted hazard ratios

of incident HF associated with a SD increase in BMI
for each menopausal age category. Model 1 was our
unadjusted analysis. In model 2, we adjusted for demographic variables; Visit 4 we adjusted for age, and
race/center groups. In model 3, we incorporated lifestyle variables and known HF risk factors, annual income, hormone therapy, cigarette smoking, alcohol
use, diabetes, hypertension, estimated glomerular
filtration rate, high-sensitivity C-reactive protein, total
cholesterol, high-density lipoprotein cholesterol, statin
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Table 2. Incidence Rates* of Heart Failure According to Obesity and Menopausal Age Categories: The ARIC Study, 1996 to
2017
Menopausal age, y
<45

Category

45– 49

50– 54

≥55

Generalized obesity
Normal weight

11.89

7.8

8.15

5.1

Overweight

12.91

12.04

8.79

9.66

Obese

21.3

16.05

13.92

16.19

Attributable risk because of overweight

1.02

4.24

0.64

4.56

Attributable risk because of obesity

9.41

8.25

5.77

11.09

Central obesity
Absent

12.32

7.49

6.85

4.77

Present

16.54

13.58

11.34

12.15

Attributable risk because of central obesity

4.22

6.09

4.49

7.38

ARIC indicates Atherosclerosis Risk in Communities.
*Incidence rates of heart failure were calculated per thousand person-years.

therapy, left ventricular hypertrophy, and prevalent coronary heart disease. MI is a strong HF risk factor21;
therefore, we included MI during follow-up in model 4
as a time-varying covariate.
There was a significant interaction between menopausal age category and WC (Pinteraction 0.001). We calculated unadjusted and adjusted hazard ratios of incident

HF associated with a SD increase in WC for each menopausal age category using a similar adjustment process.
The average age of menopause in the United States is
50 to 52 years.30 Using the 50 to 54 menopausal age
as reference, we plotted the hazard ratios of incident HF
for the other menopausal age categories separately at
rising values of BMI and WC. The proportional hazards

Figure 2. Survival probabilities for incident heart failure according to menopausal age categories
at ARIC Visit 4.
ARIC indicates Atherosclerosis Risk in Communities.
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Table 3. Hazard Ratios of Incident Heart Failure According to Menopausal Age Categories Associated With a SD Increase
in Body Mass Index and Waist Circumference: The ARIC Study, 1996 to 2017
Menopausal age category, y
<45

45– 49

50– 54

≥55

1200

1515

1468

258

HR (95% CI)

HR (95% CI)

HR (95% CI)

HR (95% CI)

Pinteraction

Model 1

1.41 (1.26–1.57)

1.35 (1.22–1.49)

1.32 (1.19–1.47)

1.63 (1.27–2.09)

0.45

Model 2

1.43 (1.27–1.60)

1.39 (1.25–1.54)

1.33 (1.20–1.48)

1.76 (1.37–2.26)

0.25

Model 3

1.35 (1.02–1.78)

1.31 (1.04–1.65)

1.01 (0.75–1.34)

1.91 (1.32–2.77)

0.05

Model 4

1.39 (1.05–1.84)

1.33 (1.06–1.67)

0.98 (0.73–1.31)

2.02 (1.41–2.89)

0.012

Number of participants*
Body mass index

Waist circumference
Model 1

1.51 (1.34–1.70)

1.50 (1.32–1.62)

1.39 (1.24–1.55)

1.87 (1.41–2.47)

0.26

Model 2

1.46 (1.29–1.64)

1.44 (1.29–1.61)

1.35 (1.21–1.53)

1.93 (1.45–2.57)

0.18

Model 3

1.26 (0.95–1.68)

1.19 (0.93–1.52)

1.02 (0.77–1.35)

2.70 (1.69–4.31)

0.004

Model 4

1.31 (0.98–1.75)

1.18 (0.92–1.52)

1.00 (0.75–1.32)

2.93 (1.85– 4.65)

0.001

SD was 6.0 kg/m2 for body mass index and 15.7 cm for waist circumference in the study sample.
Model 1, unadjusted.
Model 2, adjusted for Visit 4 age and race/center groups.
Model 3, model 2 adjusted for annual income, hormone replacement therapy use, cigarette smoking, alcohol drinking, hypertension, diabetes, total
cholesterol, high-density lipoprotein cholesterol, statin medication use, left ventricular hypertrophy, high-sensitivity C-reactive protein, glomerular filtration rate,
and prevalent coronary disease.
Model 4, model 3 adjusted for myocardial infarction during follow-up.
ARIC indicates Atherosclerosis Risk in Communities; and HR, hazard ratio.
*The number of participants refers to the number of women in each of the menopausal age categories.

assumption was tested by visual examination of the log-
log plots. P values <0.05 were considered statistically significant. Statistical analyses were performed using SAS
software version 9.4 for Windows (SAS Institute Inc., Cary,
NC).

RESULTS
The mean±SD was 63.5±5.5 years for chronological
age and 46.9±5.5 years for menopausal age at ARIC
Visit 4. The mean±SD was 47.6±5.1 years for age at
natural menopause and 43.5±5.9 years for age at surgical menopause. The mean±SD was 28.8±6.0 kg/m2
for BMI and 100.8±15.7 cm for WC at ARIC Visit 4.
Characteristics of our study participants at Visit 4 are
shown according to menopausal age categories in
Table 1. White women were more likely to experience
menopause between 50 and 54 years, while Black
women were more likely to experience menopause at
<45 years of age. Cigarette smoking, diabetes, hypertension, coronary heart disease, and elevated inflammatory markers were more common and annual
income was least among women who experienced
early menopause. Alcohol use was most common in
the 50 and 54 years menopausal age category.
Over a mean follow-
up period of 16.5±5.6 years,
we observed 903 incident HF events. The incidence
rates of HF were 15.6/1000, 12.1/1000, 10.3/1000, and
10.7/1000 person-
years for women who experienced

menopause at <45 years, 45 to 49 years, 50 to 54 years,
and ≥55 years of age, respectively. The incidence rates
of HF were greatest among women with generalized or
central obesity who had also experienced menopause
at <45 years of age, 21.3/1000 and 16.3/1000 person-
years, respectively (Table 2). However, the attributable
risk of generalized obesity, overweight, and central
obesity for HF incidence was greatest among women
who experienced menopause at ≥55 years, 11.09/1000,
4.56/1000, and 7.38/1000 person-
years, respectively.
The probability of a HF-free survival during follow-up was
lowest in women with early menopause (Figure 2). There
was a significant interaction between menopausal age
and BMI for HF incidence (Pinteraction 0.02), justifying the
presentation of our results according to menopausal age
categories. The adjusted hazard ratios of incident HF associated with a SD increase in BMI were 1.39 (1.05–1.84),
1.33 (1.06–1.67), 0.98 (0.73–1.31), and 2.02 (1.41–2.89) for
women with menopausal age <45 years, 45 to 49 years,
50 to 54, and ≥55 years, respectively. (Table 3).
There was also a significant interaction between
menopausal age and WC for HF incidence (Pinteraction
0.001). The adjusted hazard ratios of incident HF associated with a SD increase in WC were 1.31 (0.98–1.75),
1.18 (0.92–1.52), 1.00 (0.75–1.32), and 2.93 (1.85–4.65)
for women with menopausal age <45, 45 to 49, 50
to 54, and ≥55 years, respectively. (Table 3). As BMI
and WC increased, the adjusted hazard ratios of incident HF became greater in women who experienced
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Figure 3. Hazard ratios of incident heart failure according to menopausal age categories at
increasing values of body mass index.
Hazard ratios are adjusted for Visit 4 age, race/center groups, annual income, hormone therapy use,
cigarette smoking, alcohol drinking, hypertension, diabetes, total cholesterol, high-density lipoprotein
cholesterol, statin use, left ventricular hypertrophy, high-
sensitivity C-
reactive protein, glomerular
filtration rate, prevalent coronary disease, and myocardial infarction during follow-up. The 50 to 54 years
menopausal age category was used as reference. BMI indicates body mass index.

menopause at ≥55 years, when compared with the
other menopausal age categories (Figures 3 and 4).

DISCUSSION
In our study involving postmenopausal women at ARIC
Visit 4, obesity modified the association between menopausal age category and HF incidence. Although HF
incidence was greatest among women with early menopause, the attributable risk of both generalized and
central obesity for HF incidence was higher among
those who had experienced late menopause. As obesity worsened, the risk of developing HF became significantly greater when compared with women with
lower BMI and WC, particularly for those who had experienced late menopause. Maintenance of a healthy
body weight and WC may be protective against developing future HF, especially for women with late menopause. This novel finding offers insight into a possible

mechanistic basis for HF after menopause and agrees
with reports that obese women have greater cardiovascular disease risk.31
Obesity affects women of all racial and ethnic
groups.31,32 Generalized obesity is a known risk factor
for incident HF.12 The influence of generalized obesity
on the relationship between menopausal age category
and HF incidence was independent of established HF
risk factors but varied according to the reproductive
life span, with the greatest influence on women who
experienced late menopause. Obesity causes enlargement of adipocytes, resulting in adipocyte dysfunction
that is characterized by increased secretion of proinflammatory adipokines and decreased secretion of
anti-inflammatory adipokines.10 Levels of adipokines
such as adiponectin are decreased in obese individuals while leptin increases with adiposity.33 Elevated
leptin and decreased adiponectin levels are associated
with inflammation and insulin resistance,10 which are
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Figure 4. Hazard ratios of incident heart failure according to menopausal age categories at
increasing values of waist circumference.
Hazard ratios are adjusted for age, race/center groups, annual income, hormone therapy use, cigarette
smoking, alcohol drinking, hypertension, diabetes, total cholesterol, high-density lipoprotein cholesterol,
statin use, left ventricular hypertrophy, high-
sensitivity C-
reactive protein, glomerular filtration rate,
prevalent coronary disease, and myocardial infarction during follow-up. The 50 to 54 years menopausal
age category was used as reference.

known HF risk factors. Ovarian estrogen production
decreases after menopause, causing relative androgen predominance,34 and adipose tissue becomes the
major source of estrogens and androgens.10 The temporal sequence between obesity and sex hormonal
changes has previously been established in women
at midlife.35 The postmenopausal hormonal state is
characterized by estrogen deficiency and an androgenic milieu that has been associated with adverse
left ventricular remodeling in the Multiethnic Study of
Atherosclerosis.36 Menopause is also associated with
an unfavorable cardiovascular disease risk profile that
comprises known HF risk factors such as metabolic derangements, inflammation, and lipid abnormalities.2,37
Adipokines also influence androgenicity because
leptin has been associated with increased testosterone and decreased sex hormone binding globulin levels, while adiponectin has been linked with decreased
testosterone and increased sex hormone binding
globulin levels among postmenopausal women of the
ELITE study (Early versus Late Intervention Trial with

Estradiol).10 This is in congruence with reports from
SWAN (Study of Women’s Health Across the Nation)
study where greater body weight and WC predicted
an androgenic profile characterized by lower sex hormone binding globulin and higher testosterone levels
during follow-up across the menopausal transition.35
We surmised that the influence of obesity on androgenicity and subsequently HF development becomes
greater as BMI increases, with the most robust influence among women with late menopause where excess adiposity possibly counteracts the benefits of
a delay in sex hormonal changes that occur with the
menopausal transition, and the absence of excessive
adiposity of any degree may confer a protective effect
against HF development.
Central obesity is common after menopause2,34
and also predicts HF incidence.12 Central obesity
similarly modified the relationship between menopausal age category and HF incidence. This finding is
not surprising because BMI is highly correlated with
WC.13 Consequently, HF prevention in women with late
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menopause should involve monitoring both BMI and
WC, with utilization of weight loss or weight control
strategies to mitigate the adverse effects of excess
adiposity.
Our study has multiple strengths. ARIC is a prospective study with a biracial cohort and large number of participants from 4 geographic regions in the
United States. Data collection procedures and HF
events were highly standardized. We are the first to
investigate the effects of obesity on the association
between menopausal age and HF. There are also
limitations. Six hundred twenty-
six postmenopausal
women were missing information on menopausal age
at ARIC Visit 4 and were excluded from this analysis.
Menopausal age was based on self-report, but women
recall their menopausal transition with moderate accuracy.38 Because measurements of BMI and WC were
obtained at ARIC Visit 4 and not at the exact time of
menopause, weight changes may have occurred in the
interval between the onset of menopause and ARIC
Visit 4, which was our study baseline. However, the
causes of weight changes in postmenopausal women
are a subject of controversy. Evidence from the SWAN
study by Wildman et al35 offers credence to other studies that have reported that weight gain after menopause is more likely a consequence of aging rather
than the menopausal transition itself. Consequently,
we adjusted for chronological age in our analysis. The
mean menopausal age of our study participants was
46.9 years, which is less than the average range of 50
to 52 years reported in the US population. Therefore,
our findings may not be generalizable to other cohorts
but are a reflection of our study sample, which comprised 6% of women with menopausal age ≥55 years.
Our definition of incident HF in ARIC was based on ICD
codes and included events that listed HF as either the
primary or secondary diagnosis or causes of death.
Irrespective, the ARIC HF ICD classification protocol
has been evaluated previously, and performed similarly to other HF classification criteria, by exhibiting a
high specificity and poor sensitivity in identifying any
HF (decompensated or chronic).29 Risk factors such
as sex hormones and adipokines were not included in
this analysis. Information on HF subtype was available
for 500 (55.4%) HF events (those that occurred after
January 1, 2005). This included 270 (54%), 207 (41.4%),
and 23 (4.6%) cases with preserved, reduced, or recovered left ventricular ejection fraction, respectively.
Because of insufficient power, we did not perform our
analysis according to HF subtype.

CONCLUSIONS
Obesity modified the association of menopausal age
category and HF incidence. As obesity worsened,
the risk of developing HF became significantly greater
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when compared with women with lower BMI and WC,
particularly among those who had experienced menopause at ≥55 years of age. Maintenance of a healthy
body weight and waist circumference may be protective against developing HF, particularly among women
who have experienced late menopause. These findings support a public health campaign advocating
weight management in postmenopausal women, particularly among those with late menopause. Our findings should be replicated in other cohorts.
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